Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate.

Wang, Jiang-Yi; Yu, Guo-Peng; Li, Long; Lin, Guo-Wen; Ye, Ding-Wei

Wang, Jiang-Yi; Yu, Guo-Peng; Li, Long; Lin, Guo-Wen; Ye, Ding-Wei.

Afiliação

Wang JY; Department of Urology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.
Yu GP; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Li L; Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
Lin GW; Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.
Ye DW; Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200011, China.

Mil Med Res ; 9(1): 5, 2022 01 24.

Article em En | MEDLINE | ID: mdl-35074001

Assuntos

Acetato de Abiraterona; Neoplasias de Próstata Resistentes à Castração; Acetato de Abiraterona/efeitos adversos; Humanos; Masculino; Antígeno Prostático Específico; Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico; Estudos Retrospectivos

Palavras-chave

Metastatic castration-resistant prostate cancer; Overall survival; PSA decline; PSA velocity; Time to PSA progression

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Acetato de Abiraterona Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google